ITC Begins Section 337 Investigation on Photodynamic Therapy Devices, Drugs
The International Trade Commission is beginning a Section 337 investigation on allegations that imports of photodynamic therapy systems and associated pharmaceuticals from Biofrontera allegedly infringe on patents held by Sun Pharmaceutical Industries, the ITC said in a notice Aug. 1.…
Sign up for a free preview to unlock the rest of this article
If your job depends on informed compliance, you need International Trade Today. Delivered every business day and available any time online, only International Trade Today helps you stay current on the increasingly complex international trade regulatory environment.
In a complaint filed in June (see 2407030004), Sun said Biofrontera’s BF-RhodoLED XL and Ameluz prescription medicines infringe on patents related to Sun’s Blu-U Blue Light Photodynamic Therapy Illuminator device and its Levulan medication. The devices are used “particularly” to treat dermatological conditions, Biofrontera said. The ITC will consider whether to issue a limited exclusion order and cease and desist orders banning importation and sale of infringing devices and drugs from Biofrontera.